Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome

References

• Mozaffarian D, Benjamin EJ, Go AS, et al. Executive summary: heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:447–454.
   PubMed Web of Science ®Google Scholar
• Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest. 2001;107:1591–1598.
   PubMed Web of Science ®Google Scholar
• Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–2619.
   PubMed Web of Science ®Google Scholar
• Roffi M, Patrono C, Collet JP, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2015;2016(37):267–315.
   Google Scholar
• Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000;355:1936–1942.
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Park Y, et al. Novel antiplatelet agents: the current state and what is coming down the pike. Prog Cardiovasc Dis. 2015;58:267–277.
   PubMed Web of Science ®Google Scholar
• Pa G, Myat A, Kubica J, et al. State of the art: oral antiplatelet therapy. JRSM Cardiovasc Dis. 2016;5:2048004016652514.
   Web of Science ®Google Scholar
• Patrono C, Andreotti F, Arnesen H, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J. 2011;32:2922–2932.
   PubMed Web of Science ®Google Scholar
• Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Bmj. 2002;324:71–86.
   PubMed Web of Science ®Google Scholar
• Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409:202–207.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29:21–30.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–2015.
   PubMed Web of Science ®Google Scholar
• Schomig A. Ticagrelor – is there need for a new player in the antiplatelet-therapy field?. N Engl J Med. 2009;361:1108–1111.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Braunwald E, Sabatine MS. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;373:1274–1275.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368:1303–1313.
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. Jama. 2006;295:1531–1538.
   PubMed Web of Science ®Google Scholar
• Tello-Montoliu A, Tomasello SD, Ueno M, et al. Antiplatelet therapy: thrombin receptor antagonists. Br J Clin Pharmacol. 2011;72:658–671.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Flather MD, O’Donoghue ML, et al. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of thrombin-coronary artery disease trial. Circulation. 2011;123:1854–1863.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Bhatt DL, Wiviott SD, et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trial. Circulation. 2011;123:1843–1853.
   PubMed Web of Science ®Google Scholar
• Zhang P, Gruber A, Kasuda S, et al. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation. 2012;126:83–91.
   PubMed Web of Science ®Google Scholar
• Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008;51:3061–3064.
   PubMed Web of Science ®Google Scholar
• Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3:1800–1814.
   PubMed Web of Science ®Google Scholar
• Andersen H, Greenberg DL, Fujikawa K, et al. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci U S A. 1999;96:11189–11193.
   PubMed Web of Science ®Google Scholar
• Kato Y, Kita Y, Hirasawa-Taniyama Y, et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol. 2003;473:163–169.
   PubMed Web of Science ®Google Scholar
• Kraft WK, Gilmartin JH, Chappell DL, et al. Effect of vorapaxar alone and in combination with aspirin on bleeding time and platelet aggregation in healthy adult subjects. Clin Transl Sci. 2016;9:221–227.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Scirica BM, Braunwald E, et al. Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2 degrees P-TIMI 50 trial. J Am Coll Cardiol. 2014;64:2309–2317.
   PubMed Web of Science ®Google Scholar
• Doller D, Chackalamannil S, Czarniecki M, et al. Design, synthesis, and structure-activity relationship studies of himbacine derived muscarinic receptor antagonists. Bioorg Med Chem Lett. 1999;9:901–906.
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Reyderman L, Tiessen RG, et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol. 2012;68:249–258.
   PubMed Web of Science ®Google Scholar
• Goto S, Yamaguchi T, Ikeda Y, et al. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb. 2010;17:156–164.
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Hunt TL, Xuan F, et al. Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: a randomized, placebo- and positive-controlled, parallel group trial. Clin Pharmacol Drug Dev. 2014;3:18–24.
   PubMed Web of Science ®Google Scholar
• Wang A. Review of vorapaxar for the prevention of atherothrombotic events. Expert Opin Pharmacother. 2015;16:2509–2522.
   PubMed Web of Science ®Google Scholar
• Xia Y, Chackalamannil S, Greenlee WJ, et al. Discovery of a vorapaxar analog with increased aqueous solubility. Bioorg Med Chem Lett. 2010;20:6676–6679.
   PubMed Web of Science ®Google Scholar
• Ghosal A, Lu X, Penner N, et al. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist. Drug Metab Dispos. 2011;39:30–38.
   PubMed Web of Science ®Google Scholar
• Tantry US, Liu F, Chen G, et al. Vorapaxar in the secondary prevention of atherothrombosis. Expert Rev Cardiovasc Ther. 2015;13:1293–1305.
   PubMed Web of Science ®Google Scholar
• Statkevich P, Kosoglou T, Preston RA, et al. Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment. Eur J Clin Pharmacol. 2012;68:1501–1508.
   PubMed Web of Science ®Google Scholar
• Tricoci P, Chen E, Neely ML, et al. Abstract 17658: CYP2C19 polymorphism and PON-1 activity in NSTE ACS: vorapaxar effect in relation to clopidogrel metabolism in the TRACER trial. Circulation. 2013;128:A17658–A.
   Web of Science ®Google Scholar
• Friedman EA, Texeira L, Delaney J, et al. Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention. J Thromb Thrombolysis. 2016;41:656–662.
   PubMed Web of Science ®Google Scholar
• Edelstein LC, Simon LM, Lindsay CR, et al. Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood. 2014;124:3450–3458.
   PubMed Web of Science ®Google Scholar
• Hawes BE, Zhai Y, Hesk D, et al. In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist. Eur J Pharmacol. 2015;762:221–228.
   PubMed Web of Science ®Google Scholar
• Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009;373:919–928.
   PubMed Web of Science ®Google Scholar
• Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366:20–33.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404–1413.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Tricoci P, Huang Z, et al. Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER trial). Am J Cardiol. 2014;114:665–673.
   PubMed Web of Science ®Google Scholar
• Cornel JH, Tricoci P, Lokhnygina Y, et al. Glycoprotein IIb/IIIa receptor inhibitors in combination with vorapaxar, a platelet thrombin receptor antagonist, among patients with non-ST-segment elevation acute coronary syndromes (from the TRACER trial). Am J Cardiol. 2015;115:1325–1332.
   PubMed Web of Science ®Google Scholar
• Held C, Tricoci P, Huang Z, et al. Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. Eur Heart J Acute Cardiovasc Care. 2014;3:246–256.
   PubMedGoogle Scholar
• Whellan DJ, Tricoci P, Chen E, et al. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J Am Coll Cardiol. 2014;63:1048–1057.
   PubMed Web of Science ®Google Scholar
• Jones WS, Tricoci P, Huang Z, et al. Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). Am Heart J. 2014;168:588–596.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Alberts MJ, Mohr JP, et al. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013;44:691–698.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial. Lancet. 2012;380:1317–1324.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation. 2013;127:1522-9,9e1-6.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Bhatt DL, Goto S, et al. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials. J Thromb Haemost. 2012;10:2006–2015.
   PubMed Web of Science ®Google Scholar
• Bhal V, Herr MJ, Dixon M, et al. Platelet function recovery following exposure to triple anti-platelet inhibitors using an in vitro transfusion model. Thromb Res. 2015;136:1216–1223.
   PubMed Web of Science ®Google Scholar
• Cai TQ, Wickham LA, Sitko G, et al. Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist. Eur J Pharmacol. 2015;758:107–114.
   PubMed Web of Science ®Google Scholar
• Kosova EC, Bonaca MP, Dellborg M, et al. Vorapaxar in patients with coronary artery bypass grafting: findings from the TRA 2 degrees P-TIMI 50 trial. Eur Heart J Acute Cardiovasc Care. 2016. Apr 13. pii: 2048872616644910
   PubMedGoogle Scholar
• Van Diepen S, Tricoci P, Podder M, et al. Efficacy and safety of vorapaxar in non-ST-segment elevation acute coronary syndrome patients undergoing noncardiac surgery. J Am Heart Assoc. 2015;4:e002546.
   Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Kumar B, et al. The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar. J Clin Pharmacol. 2013;53:540–549.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Kuliopulos A, Tantry US. G-protein-coupled receptors signaling pathways in new antiplatelet drug development. Arterioscler Thromb Vasc Biol. 2015;35:500–512.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol. 2005;46:1820–1826.
   PubMed Web of Science ®Google Scholar
• Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155–2166.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Sechtem U, Achenbach S, et al. ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;2013(34):2949–3003.
   Google Scholar